General Information of Drug Transporter (DT)
DT ID DTD0111 Transporter Info
Gene Name SLC16A7
Transporter Name Monocarboxylate transporter 2
Gene ID
9194
UniProt ID
O60669
Post-Translational Modification of This DT
Overview of SLC16A7 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-O-glycosylation X-Phosphorylation X-Ubiquitination X: Amino Acid

O-glycosylation

  Serine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC16A7 [1] , [2]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

465

Experimental Method

Co-Immunoprecipitation

Detailed Description

O-linked Glycosylation at SLC16A7 Serine 465 has the potential to affect its expression or activity.

Phosphorylation

  Serine

        14 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC16A7 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

177

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 177 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC16A7 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

183

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 183 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC16A7 [3]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

193

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 193 has the potential to affect its expression or activity.

  PTM Phenomenon 4

Have the potential to influence SLC16A7 [4] , [5]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

218

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 218 has the potential to affect its expression or activity.

  PTM Phenomenon 5

Have the potential to influence SLC16A7 [4] , [5]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

219

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 219 has the potential to affect its expression or activity.

  PTM Phenomenon 6

Have the potential to influence SLC16A7 [6] , [7]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

240

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 240 has the potential to affect its expression or activity.

  PTM Phenomenon 7

Have the potential to influence SLC16A7 [8]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

281

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 281 has the potential to affect its expression or activity.

  PTM Phenomenon 8

Have the potential to influence SLC16A7 [4] , [9]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

448

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 448 has the potential to affect its expression or activity.

  PTM Phenomenon 9

Have the potential to influence SLC16A7 [10] , [11]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

452

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 452 has the potential to affect its expression or activity.

  PTM Phenomenon 10

Have the potential to influence SLC16A7 [12] , [13]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

454

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 454 has the potential to affect its expression or activity.

  PTM Phenomenon 11

Have the potential to influence SLC16A7 [12] , [13]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

457

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 457 has the potential to affect its expression or activity.

  PTM Phenomenon 12

Have the potential to influence SLC16A7 [14] , [15]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

465

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 465 has the potential to affect its expression or activity.

  PTM Phenomenon 13

Have the potential to influence SLC16A7 [16] , [17]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

469

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 469 has the potential to affect its expression or activity.

  PTM Phenomenon 14

Have the potential to influence SLC16A7 [4] , [17]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

472

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Serine 472 has the potential to affect its expression or activity.

  Threonine

          3 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC16A7 [11] , [18]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

445

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Threonine 445 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC16A7 [4] , [17]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

471

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Threonine 471 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC16A7 [16] , [17]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

476

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A7 Threonine 476 has the potential to affect its expression or activity.

Ubiquitination

  Lysine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC16A7 [19]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

463

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC16A7 Lysine 463 has the potential to affect its expression or activity.
References
1 Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease. J Pathol. 2017 Sep;243(1):78-88.
2 Synthesis of a Highly Azide-Reactive and Thermosensitive Biofunctional Reagent for Efficient Enrichment and Large-Scale Identification of O-GlcNAc Proteins by Mass Spectrometry. Anal Chem. 2017 Jun 6;89(11):5810-5817.
3 Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. Mol Cell Proteomics. 2017 Apr;16(4):663-679.
4 Robust, Reproducible, and Economical Phosphopeptide Enrichment Using Calcium Titanate. J Proteome Res. 2019 Mar 1;18(3):1411-1417.
5 MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene. 2018 Aug;37(33):4518-4533.
6 Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
7 Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator. Proteomics. 2017 Nov;17(22):10.1002/pmic.201700214.
8 Quantitative global phosphoproteomics of human umbilical vein endothelial cells after activation of the Rap signaling pathway. Mol Biosyst. 2013 Apr 5;9(4):732-49.
9 Global phosphoproteomics of CCR5-tropic HIV-1 signaling reveals reprogramming of cellular protein production pathways and identifies p70-S6K1 and MK2 as HIV-responsive kinases required for optimal infection of CD4+ T cells. Retrovirology. 2018 Jul 3;15(1):44.
10 Tip-Based Fractionation of Batch-Enriched Phosphopeptides Facilitates Easy and Robust Phosphoproteome Analysis. J Proteome Res. 2018 Jan 5;17(1):46-54.
11 Defeating Major Contaminants in Fe3+- Immobilized Metal Ion Affinity Chromatography (IMAC) Phosphopeptide Enrichment. Mol Cell Proteomics. 2018 May;17(5):1028-1034.
12 Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition. Blood. 2017 Jan 12;129(2):e1-e12.
13 Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3175-3180.
14 Protein kinase C-alpha interaction with F0F1-ATPase promotes F0F1-ATPase activity and reduces energy deficits in injured renal cells. J Biol Chem. 2015 Mar 13;290(11):7054-66.
15 Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 2014 Sep 11;8(5):1583-94.
16 An integrated strategy for highly sensitive phosphoproteome analysis from low micrograms of protein samples. Analyst. 2018 Jul 23;143(15):3693-3701.
17 A Methodological Assessment and Characterization of Genetically-Driven Variation in Three Human Phosphoproteomes. Sci Rep. 2018 Aug 14;8(1):12106.
18 HIV-1 Activates T Cell Signaling Independently of Antigen to Drive Viral Spread. Cell Rep. 2017 Jan 24;18(4):1062-1074.
19 Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell. 2011 Oct 21;44(2):325-40.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.